Abstract Number: 356 • 2014 ACR/ARHP Annual Meeting
The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Background/Purpose: The Rheumatoid arthritis impact of disease (RAID) score is a relatively new patient-derived composite score assessing the seven most important domains of the impact…Abstract Number: 2682 • 2013 ACR/ARHP Annual Meeting
Incidence Trends and Predictors Of Orthopedic Surgery In Patients With Rheumatoid Arthritis – Results From a Well Defined Population
Background/Purpose: Orthopedic surgery is used effectively in many patients with severe rheumatoid arthritis (RA). The aim of modern pharmacologic treatment is to prevent joint destruction…Abstract Number: 2371 • 2013 ACR/ARHP Annual Meeting
Is a Single Variable, The Swollen Joint Count, Valid As An Outcome Measure Separate From Being In An Index Measure? An Analysis From The Prospective, Biologic Treatment Registry Across Canada
Background/Purpose: The importance of joint counts as measures of synovitis is reflected in their prominence in all major clinical composite indices, the Disease Activity Score…Abstract Number: 2279 • 2013 ACR/ARHP Annual Meeting
Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database
Background/Purpose: Dissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global…Abstract Number: 2287 • 2013 ACR/ARHP Annual Meeting
What Is The Internal Consistency Of The Disease Activity Score (DAS)-28 In Rheumatoid Arthritis Patients Treated In a Real–World Setting?
Background/Purpose: The DAS-28 is used in clinical decision making and research as an outcome assessment for patients with RA. The tool measures clinical, patient centric…Abstract Number: 2239 • 2013 ACR/ARHP Annual Meeting
Validation Of a Patient Reported Experience Measure In Patients With Rheumatoid Arthritis
Background/Purpose: Improving patient experience is important in all diseases, but most important in patients with chronic rheumatic diseases like rheumatoid arthritis. To date there…Abstract Number: 1972 • 2013 ACR/ARHP Annual Meeting
Erosion Case Definition and Scoring Reliability Exercise Using a New Outcome Measurement Tool, High-Resolution Peripheral Quantitative Computed Tomography, In Rheumatoid Arthritis
Background/Purpose: High-resolution peripheral quantitative computed tomography (HR-pQCT) is a novel imaging instrument for bony damage in rheumatoid arthritis (RA). Agreement on a case definition for…Abstract Number: 1973 • 2013 ACR/ARHP Annual Meeting
Importance Of Hand Positioning In 3D Joint Space Morphology Assessment
Background/Purpose: Precise quantification of joint space morphology (JSM) is an important factor for early diagnosis and monitoring of disease activity and therapeutic responses in rheumatoid…Abstract Number: 2109 • 2012 ACR/ARHP Annual Meeting
Discrepancy Between Patient and Physician Global Assessments Over Time in Early Rheumatoid Arthritis
Background/Purpose: Discrepancy between patient (PGA) and physician (MDGA) global assessments in RA can adversely affect therapeutic decisions in many cases. The purpose of this study…Abstract Number: 1698 • 2012 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologics in 2,281 US Patients with Rheumatoid Arthritis
Background/Purpose: Identifying predictors of discontinuation of biologic treatment for Rheumatoid Arthritis (RA) has clinical and research importance given the chronicity of RA and high costs…Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…Abstract Number: 1045 • 2012 ACR/ARHP Annual Meeting
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Wrist in Rheumatoid Arthritis Patients Treated with Methotrexate, Intra-Articular Glucocorticoid and Adalimumab/Placebo
Background/Purpose: To validate parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in an early rheumatoid arthritis (RA) clinical trial by comparison with clinical parameters of…Abstract Number: 769 • 2012 ACR/ARHP Annual Meeting
2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria Predicts Radiogical, but Not Clinical Outcomes At 18 Months Into Disease in a Canadian Early Arthritis Cohort
Background/Purpose: The potential of the 2010 ACR/EULAR rheumatoid arthritis (RA) classification criteria to discriminate early arthritis patients according to their clinical and radiological outcomes needs…Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…Abstract Number: 421 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not Antibodies to Citrullinated Proteins, Are Associated with High Disease Activity
Background/Purpose: Autoantibodies in general, and rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) in particular, are a hallmark of RA. After their characterization, ACPA have…